Be the first to review this item
Alflutop - regulates the metabolism in the cartilaginous tissue. The composition of the marine fish extract includes glycosaminoglycans: hyaluronic acid, chondroitin-6-sulfate, chondroitin-4-sulfate, dermatan sulfate, keratan sulfate; amino acids; polypeptides (with a molecular weight of 50,000 daltons); macro- and microelements: sodium, potassium, calcium, magnesium, iron, zinc, copper.
Alflutop has a chondroprotective effect, based on the inhibition of the activity of hyaluronidase and other enzymes, which take part in the destruction of the intercellular matrix and normalize the biosynthesis of hyaluronic acid and type II collagen. These effects are synergistic and cause the activation of the processes of restoring the structure of the cartilage and prevent the destruction of macromolecular structures of normal cartilaginous tissues.
Alflutop, restoring the homeostasis in the joint, inhibits the biosynthesis of inflammatory mediators, including pro-inflammatory cytokines. As a result, it has a pronounced anti-inflammatory and analgesic effect, which manifests itself on the 8-10th day of treatment.
Proteoglycans, which are part of the drug, have a trophic effect and have a substitution effect, significantly increasing the MRI values of hydrophilicity, cartilage height and bone homogeneity.
In diseases of the gastrointestinal tract, Alflutop has a gastroprotective effect. The drug restores the synthesis of prostaglandins, reduces the time of epithelization of ulcerative and erosive defects in NSAIDs with gastropathies against the background of antiulcer therapy. It can serve as a drug of choice in patients with developed NSAID-gastropathy in case of need to continue analgesic and anti-inflammatory therapy.
It is not recommended to prescribe the drug in childhood and adolescence because of the lack of clinical data that confirm the safety and effectiveness of its use in this age group.
The drug is administered to adults.
With polyosteoarthrosis and osteochondrosis, Alflutop is injected deep in the / m at 10 mg (1 ml) per day. The course of treatment - 20 injections.
With the primary lesion of large joints, the drug is injected into the joint 10-20 mg (1-2 ml) with an interval between injections 3-4 days. The course of treatment - 5-6 injections in each joint.
More effectively combined use of / m and intraarticular injections.
If necessary, the course of treatment should be carried out after 3 months, after 6 months.
Rarely: itching dermatitis, redness of the skin, burning sensation at the injection site, short-term myalgia.
Very rarely: anaphylactic reactions.
In some cases: a transient increase in pain syndrome (with intra-articular injection).
Important notice- the outer box design may vary before prior notice!
Someone from the Canada - just purchased the goods:
Ceraxon injection 1000mg/4ml 5 vials